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Abstract
Background: Chinese herbs are thought to be effective for type A H1N1 influenza. Series of Chinese herbs have been
authorized recommended by the Chinese government, and until now a number of clinical trials of Chinese herbs for H1N1
influenza have been conducted. However, there is no critically appraised evidence such as systematic reviews or meta-
analyses on potential benefits and harms of medicinal herbs for H1N1 influenza to justify their clinical use and their
recommendation.
Methods and Findings: CENTRAL, MEDLINE, EMBASE, CBM, CNKI, VIP, China Important Conference Papers Database, China
Dissertation Database, and online clinical trial registry websites were searched for published and unpublished randomized
controlled trials (RCTs) of Chinese herbs for H1N1 influenza till 31 August, 2011. A total of 26 RCTs were identified and
reviewed. Most of the RCTs were of high risk of bias with flawed study design and poor methodological quality. The
combination of several Chinese herbal medicines with or without oseltamivir demonstrated positive effect on fever
resolution, relief of symptoms, and global effectiveness rate compared to oseltamivir alone. However, only one herbal
medicine showed positive effect on viral shedding. Most of the trials did not report adverse events, and the safety of herbal
medicines is still uncertain.
Conclusions: Some Chinese herbal medicines demonstrated potential positive effect for 2009 type A H1N1 influenza;
however, due to the lack of placebo controlled trial and lack of repeated test of the intervention, we could not draw
confirmative conclusions on the beneficial effect of Chinese herbs for H1N1 influenza. More rigorous trials are warranted to
support their clinical use.
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Introduction
The influenza virus, known to be a circulating pathogen in the
human population since the 16th century, is notable for its unique
ability to cause recurrent epidemics and global pandemics. The
ability of this virus to undergo genetic reassortments causes
unpredictable changes in its antigens and the consequent immune
response leads to recurrent epidemics of febrile respiratory disease
every 1–3 years. In the 20th, three influenza pandemics occurred
and killed tens of millions of people, with each of these pandemics
being caused by the appearance of a new strain of the virus in
humans [1]. In April 2009 a novel flu strain evolved that combined
genes from human, pig, and bird flu, initially dubbed ‘swine flu’
and also known as influenza A/H1N1, emerged in Mexico, the
United States, and several other nations. The World Health
Organization officially declared the outbreak to be a pandemic on
June 11, 2009 [2].
Presently, two classes of antiviral drugs have been approved by
the US Food and Drug Administration (FDA) in treating or
preventing influenza virus infections: M2 ion channel blockers and
neuraminidase inhibitors (NAIs). The M2 blockers, amantidine
and rimantidine, are effective against influenza A viruses, but not
influenza B viruses, which lack the M2 protein. However, use of
the M2 blockers has been associated with the rapid emergence of
drug-resistance mutations of the M2 protein among human
influenza A viruses of H3N2 subtype and H1N1 subtypes
circulating in certain geographic areas [3]. Two NAIs, oseltamivir
(Tamiflu) and zanamivir (Relenza) are approved by US FDA for
use against type A and type B influenza infections. The NAIs
target the active site of the NA protein, inhibiting its sialidase
activity that is essential for virus release. Most of the influenza virus
strains are sensitive to oseltamivir. However, it has been thought
that the development of drug resistance may limit the clinical
utility of the drug in the future [4].
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Traditional Chinese medicine (TCM), are widely used in China.
Due to the limitation of healthcare resources and high cost of
antiviral drugs, Chinese herbs have been recommended for
preventing and treating influenza in China, especially for poor
regions. In October 2009, the Ministry of Health of China issued
‘Guidelines for Management of Pandemic (H1N1) 2009 Influen-
za’, and recommended series of Chinese herbs for the treatment of
type A H1N1 influenza, including herbal products extracted from
natural herbs, Chinese patent medicine (including herbal injec-
tion), and principles for individually prescribed herbal decoction
[5].
Until now, a number of clinical trials of Chinese herbs for
H1N1 influenza have been conducted and reported with positive
findings. However, there is no critically appraised evidence such as
systematic reviews or meta-analyses on potential benefits and
harms of medicinal herbs for H1N1 influenza to justify their
clinical use and their recommendation.
Methods
The supporting PRISMA checklist is available as supporting
information; see Checklist S1.
Search strategy and study selection
Literature searches were conducted in the Cochrane Central
Register of Controlled Trials (CENTRAL) in the Cochrane
Library (January, 2011), MEDLINE, EMBASE, Chinese Bio-
Medical Literature Database (CBM), Chinese National Knowl-
edge Infrastructure (CNKI), Chinese Scientific Journal Database
(VIP), China’s Important Conference Papers Database, and
China’s Dissertation Database from their inception to 31 August,
2011. Ongoing registered clinical trials were searched in the
website of Chinese clinical trial registry (http://www.chictr.org/)
and international clinical trial registry by U.S. national institutes of
health (http://clinicaltrials.gov/). The following search terms were
used individually or combined: ‘influenza’, ‘H1N1 influenza’,
‘Chinese Traditional’, ‘Chinese Herbal’, ‘Oriental Traditional’,
‘herb’, ‘herbal medicine’, ‘clinical trial’, and ‘randomized
controlled trial’.
Two authors conducted the literature searching (WC, CEDL),
study selection (WC, CEDL), and data extraction (WC, HJK)
independently. The extracted data included authors and title of
study, year of publication, study size, age and sex of the
participants, details of methodological information, name and
component of Chinese herbs, treatment process, details of the
control interventions, outcomes (for example, total effective rate),
and adverse effects for each study. Disagreement was resolved by
discussion and reached consensus through a third party (JPL).
Inclusion criteria
Parallel randomized controlled trials (RCTs) of Chinese herbs
compared with no treatment, symptomatic treatment, placebo, or
antivirus for H1N1 patients were included. Combined therapy of
Chinese herbs and other interventions compared with other
interventions in RCTs was also included. Chinese herbs included
herbal products extracted from natural herbs, Chinese patent
medicine, or individually prescribed herbal formula. The primary
outcome measures were duration of fever (the average time for
fever to clear), duration of flu-like symptoms (the average time for
flu-like symptoms to disappear), and global effectiveness rate
(defined as a three-class measurement including ‘cure’, ‘effective’,
and ‘ineffective’ according to the degree of overall symptom
improvement). The secondary outcome measures were hospital
stay (number of days in hospital), viral shedding, and adverse
events. Multiple publications reporting the same groups of
participants were excluded. There was no limitation on language
and publication type.
Trial quality assessment
Two authors (WC, CEDL) evaluated the quality of included
trials. The quality of included trials were assessed by using the ‘risk
of bias’ assessment tool according to the ‘Cochrane Handbook of
Systematic Reviews of Interventions’ (Chapter 8.5) to address the
following five criteria [6]: sequence generation, allocation
concealment, blinding, incomplete outcome data, and selective
outcome reporting. The quality of all the included trials was
categorized to low/unclear/high risk of bias. Trials which met all
criteria were categorized to low risk of bias, trials which met none
of the criteria were categorized to high risk of bias, and other trials
were categorized to unclear risk of bias if insufficient information
acquired to make judgment.
Data analysis
Data were summarized using relative risk (RR) with 95%
confidence intervals (CI) for binary outcomes or mean difference
(MD) with 95% CI for continuous outcomes. Revman 5.0.17
software was used for data analyses. Meta-analysis was used if the
trials had a good homogeneity on study design, participants,
interventions, control, and outcome measures, which assessed by
examining I
2 (a quantity that describes approximately the
proportion of variation in point estimates due to heterogeneity
rather than sampling error). Publication bias would explored by
funnel plot analysis if sufficient studies were found. If we had
identified a sufficient number of randomized trials, we had
planned to perform sensitivity analyses to explore the influence of
trial quality on effect estimates. The quality components of
methodology included adequacy of generation of allocation
sequence, concealment of allocation, double blinding, and the
use of intention -to -treat (yes or no).
Results
Description of studies
A flow chart depicted the search process and study selection
(Fig. 1). After primary searches from the seven databases, 270
citations were screened. After reading the titles and abstracts, a
majority of them was excluded. Full text of 46 papers were
retrieved, and finally 26 RCTs were included [7–32] including two
three-armed RCTs [16,31] and four four-armed RCTs
[17,21,24,27]. All the RCTs were conducted in China and
published in Chinese, except one published in English [24].
Twenty papers were excluded [33–52], and the reasons for
excluded studies were listed in Table S3.
The search for ongoing registered trials identified four trials:
three RCTs from the website of Chinese clinical trial registry:
No. ChiCTR-TRC-10000828 investigating herbal anti-virus liq-
uid for H1N1 influenza A; No. ChiCTR-TRC-10000814 inves-
tigating Reduning herbal injection for H1N1 influenza A; and
ChiCTR-TRC-10000779 investigating TCM treatment for H1N1
influenza. All the three RCTs were either under participant
recruitment or not initiated and thus the data were not available.
One RCT was identified from www.clinicaltrials.gov:
NCT01053533 investigating Chinese herbal medicines (details
not provided) plus western medicine for H1N1 influenza A. This
trial was under recruitment and data were not available.
The characteristics of included trials were listed in Table S1. A
total of 2946 participants with H1N1 influenza were involved with
Chinese Herbal Medicines for Type A H1N1 Influenza
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participants got influenza during the H1N1 influenza epidemic year
of 2009 and were virologically confirmed as having 2009-H1N1
influenza according to Chinese Center For Disease Control And
Prevention (CDC). Seven trials [7,8,10,14,18,28,32] provide
information on patients’ syndrome differentiation (Bianzheng,
TCM diagnosis) as the basis for individualized herbal preparations.
A totalof 27 different Chineseherbswere investigated.TheChinese
herbs investigated included Chinese patent medicine including
single herb extract [9,10,11,16,23,25,29], and individually pre-
scribed herbal formula [8,12–15,18–20,22,24,26–28,30,32], in
some trials [7,17,21,31], mixed herbal medicines including multiple
Chinese herbal prescription or Chinese patent medicines were
tested. The specific compositions of these Chinese herbs varied as
shown in Table S4. Only one trial reported the quality standard of
the herbal preparations [24]. The total treatment duration ranged
from 3 to 14 days. The controls included symptomatic treatment
[8,21], placebo [16,27], and oseltamivir [7,9–15,17–20,22,23,25–
32]. The reported outcome measures included duration of fever,
duration offlu-likesymptoms,globaleffectivenessrate,hospitalstay,
viral response, and adverse events.
Methodological quality
The majority of the included trials were assessed to be of general
poor methodological quality according to the predefined quality
assessment criteria. The randomized allocation of participants was
mentioned in all trials; however, only 6 trials stated the methods
for sequence generation including random number table
Figure 1. PRISMA 2009 Flow Diagram.
doi:10.1371/journal.pone.0028093.g001
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insufficient information was provided to judge whether or not it
was conducted properly. Allocation concealment was only
mentioned in one RCT [24]. Double-blind was not mentioned
in all trials. Single blind was mentioned in one trial [7] without
providing further information as to who was blinded. However, as
the testing Chinese herbs and controlled drug were in different
forms (liquid versus tablet), neither the participants nor the
investigators were likely to be blinded. Only two trials reported
drop-out or withdraw [7,24], however the trial did not intend to
analyze the cause, and no trials used intention-to-treat analysis.
Only one trial [24] had a pre-trial estimation of sample size, which
indicated the lack of statistical power to ensure appropriate
estimation of the therapeutic effect. Selective reporting was
generally unclear in the RCTs due to the inaccessibility to the
trial protocol.
Effect estimates
All the trials claimed positive effect favoring Chinese herbs
though some of the trials turned out to be negative when analyzed
by standard statistical techniques using risk ratios or mean
differences. The effect estimates of Chinese herbs were shown in
the Table S2.
1. Duration of fever. A total of seventeen trials [7–
9,12,13,15–17,19–21,23,24,27,28,29,31,32] reported the effect of
Chinese herbs individually or in combination with oseltamivir on
defervescence. Among them, eight trials demonstrated better effect
favoring Chinese herbs: Fanggan Granule [8] mildly shortened
fever duration than symptomatic treatment; Bingyanqing formula
Ten [20] and Chinese herbal formula [17] had shorter fever
duration than oseltamivir; the combination of Maxingshigan-
yinqiaosan and oseltamivir had more proportion of patients who
became afebrile than no intervention [24], Maxingshigan
decoction combined with oseltamivir had shorter fever duration
than placebo of oseltamivir [27]; Maxingshigan decoction
combined with placebo of oseltamivir had shorter fever duration
than placebo of oseltamivir [27]; self-prescribed herbal medicines
had shorter fever duration than oseltamivir [28]; the combination
of Gegen Granule [32] and oseltamivir, Tanreqing Injection
[13,19] and oseltamivir, Chinese herbal formula [17] and
oseltamivir had mildly shorter fever duration than oseltamivir
alone.
The forest plot of comparison of CHM versus oseltamivir for
the outcome of duration of fever was shown in the Figure S1.
2. Duration of flu-like symptoms. Nine trials [7–
9,14,16,23,27,29,31] reported the effect of Chinese herbs
individually or in combination with oseltamivir on the duration of
flu-like symptoms. Among them, two trials demonstrated better
effect favoring Chinese herbs: Qingwen Tuire Decoction combined
with oseltamivir shortened the duration of flu-like symptoms
compared to oseltamivir alone [29], and Fanggan Granule had
shorter duration of flu-like symptoms compared to symptomatic
treatment [8].
3. Global effectiveness rate. Eleven trials [8,10,11,13,17,
18,22,25–28] reported the effect of Chinese herbs individually or in
combination with oseltamivir on the global effectiveness rate. Among
them, six trials demonstrated better effect favoring Chinese herbs:
Qingfei Jiedu Decoction [10] showed better effect compared to
oseltamivir, the combinations of oseltamivir and Tanreqing Injection
[11,13], oseltamivir and Xiyanping Injection [22] had better effect
compared to oseltamivir alone, Qingjie Huashi decoction showed
better effect compared to oseltamivir [25], and the combination of
Reduning Injection [26] and ribavirin plus oseltamivir had better effect
compared to ribavirin plus oseltamivir.
4. Hospital stay. Six trials [7,14,16,17,19,27] reported the
effect of Chinese herbs individually or in combination with
oseltamivir on hospital stay. Among them, two trials demonstrated
better effect favoring Chinese herbs: one herbal formula showed
shorter hospital stay compared to oseltamivir [17], and Tanreqing
Injection combined with oseltamivir had shorter hospital stay
compared to oseltamivir alone [19].
5. Viral shedding. Ten trials [9,12,14,15,17,19,21,28,30,31]
reported the effect of herbal medicines individually or in
combination with oseltamivir on viral shedding. Among them,
one self-prescribed herbal medicines showed better effect compared
with oseltamivir [28].
6. Adverse events. As shown in Table S2, the outcome of
adverse events were reported in fifteen trials [7,8,10,12,14–
18,22,24,25,27,30,31]. Among them, no adverse events were
found in three trial [12,14,15,31]. Six trials reported adverse
events in Chinese herbs group, which included diarrhea [7,8,16],
arrhythmia [8], mild nausea [17,24], vomit [24], mild upper
abdominal discomfort [17], and lung infection [18]. In the trial of
Tang 2010 [22], two cases of wheal were identified, but did not
report in which group it occurred.
We conducted funnel plots to investigate the publication bias
(see Figure S2). It demonstrated asymmetrical funnel plots,
suggesting potential publication bias.
Discussion
In this review, several Chinese herbal medicines demonstrated
potential positive effect for 2009 type A H1N1 influenza on fever
resolution, relief of flu-like symptoms, and global effectiveness rate.
However, due to the lack of placebo controlled trial and lack of
repeated test, we could not make confirmative conclusions on the
therapeutic effect of Chinese herbs for H1N1 influenza. In
addition, we found out that few Chinese herbs recommended in
the ‘Guidelines for Management of Pandemic (H1N1) 2009
Influenza’ issued by the Ministry of Health of China were
supported in this review, which revealed the lack of evidence for
clinical use and policy making in China.
The following reasons might contribute to the inconclusive
results of Chinese herbs. Firstly, all the included trials were of poor
methodology quality, which were in accordance with previous
studies [53,54]. Only six RCTs stated randomization procedure,
however, most of them provided insufficient information to judge
whether randomization was conducted properly. For the rest
fourteen trials, they just mentioned that ‘the patients were
randomized into two groups’ with no further information.
Allocation concealment was only mentioned in one RCT.
Therefore, we could not exclude the possibility that some of these
claimed RCTs are not real RCTs. This possibility came to
forefront in the trial of Han 2011 and Li 2010 [11,13]; these trials
only has one author, which is impossible for a RCT to be done
properly in terms of randomization procedure and the allocation
concealment. In addition, no trials claimed double-blind. We
understood that it was difficult to perform double-blinding because
of certain features associated with Chinese herbs, for example,
aroma and appearance, but blinding to the outcome assessors and
data analyzer could be feasible. Unfortunately, none of the RCTs
mentioned blinding to the outcome assessors or data analyzer. All
the trials did not report pre-sample size estimation except one
[24], and for majority trials, the sample size was small. Therefore
we are not sure if they could provide enough power to detect the
difference between groups. It is well known that methodologically
poorly designed trials show larger differences between experimen-
tal and control groups than those conducted rigorously [55–57]
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regarded with caution.
Secondly, there was lack of knowledge for placebo control in the
included trials. Two trials [16,27] claimed that they used placebo
control. However, in these trials the placebo is for oseltamivir, not
for Chinese herbs. It is not an appropriate control for the
estimation of the effect of Chinese herbs. Because of the lack of
placebo controls, the interpretation of the positive findings of
treatment with Chinese herbs should be made with caution. In
addition, the potential positive placebo effect of an injection should
also be highlighted. In the review a total of three Chinese herbal
injections were used, that is, Tanreqing Injection [11,13],
Xiyanping Injection [22], and Reduning Injection [26]; and all
demonstrated positive results in terms of defervescence and global
symptoms improvement. However, no adequate placebo control
was used to offset the effect of injection alone. It is known that an
injection alone has a strong potential placebo effect, therefore the
overall effect of Chinese herbal injection could not rule out the
effect that the injection itself produced. These positive effects
should also be interpreted conservatively.
Thirdly, in most of the trials, the patients were not treated
according to syndrome differentiation. In the practice of TCM,
herbal preparations should match the type of syndrome differen-
tiation, that is, ‘bianzheng’, a specific diagnosis in TCM. This
approach is also known as treatment based on individualized
(tailored) syndrome pattern, and is thought to be the advantages of
TCM. However, in this review, only seven trials provide
information on patients’ syndrome differentiation. Chinese
medicine practitioners believed that treating patients without
syndrome differentiation will impair the advantages of Chinese
herbs, and this might be another reason for the unsatisfactory
therapeutic effect of Chinese herbs for H1N1 influenza in the
review. Emphasis should be paid to encourage authors to explain
each ‘Bianzheng’ by using common medical terms in the future
trials, therefore making it understandable by physicians and
consumers.
Finally, there existed great heterogeneity in the Chinese herbs
investigated in the review. A total of 27 different Chinese herbs
were investigated in the 26 trials. As a result, it is impossible to
conduct meaningful meta-analysis for a specific Chinese herb, or
difficult to undertake subgroup analyses to explore specific factors
that may have an impact on the effects of the treatment regimen.
What is more interesting is that although diversified Chinese herbs
were investigated, most of them were not the authoritatively
recommended Chinese herbs for the H1N1 influenza. In October
2009, the Ministry of Health of China issued ‘Guidelines for
Management of Pandemic (H1N1) 2009 Influenza A’ and
recommended series of Chinese herbs for the treatment of
H1N1 influenza A [5]. These Chinese herbs included herbal
products extracted from natural herbs, Chinese patent medicines
(including herbal injection), and principles for prescribing
individually herbal decoction. However, only three Chinese patent
medicines (Lianhuaqingwen Capsule [12,15,17,18], Xiyanping
Injection [22], Tanreqing Injection [11,13,19]) and two prescript
Chinese herbal decoction (unnamed Self-prescribed Chinese
herbal decoction [9], and Qingfei Jiedu Decoction [10]) in the
guideline had been investigated by RCTs, and only two of them
(Tanreqing Injection [11,13,19] and Qingfei Jiedu Decoction [10])
demonstrated positive results. World Health Organization (WHO)
calls for evidence-based practice of TCM, that is, any medical
decision-making of TCM should be based on clinical research
evidence. In the era of evidence-based medicine (EBM), TCM is
facing a big challenge because of the lack of a rigorous research
evidence base. Our review revealed the lack of evidence for clinical
use and policy making of Chinese herbs for H1N1 influenza in
China. There is still a long way to go for evidence-based practice
of TCM.
In addition, our review found inadequate reporting on adverse
events in the included trials. Eleven trials did not mention whether
they had monitored adverse effects at all. Conclusions about the
safety of herbal medicines cannot be drawn from this review due to
the limited, inadequate recording and reporting of adverse events.
Even for the trials that reported adverse events, their report was
very brief, providing limited information. In China, there is a
general perception that it is safe to use herbal medicines for
various conditions. However, with the increasing reports of liver
toxicity and other adverse events associated with Chinese herbal
medicines [58–60], more emphasis should be placed on the
monitoring and reporting of adverse events to justify the safety of
Chinese herbs in clinical trials in the future.
The funnel plot analysis showed asymmetry which suggests the
possibility of publication bias of Chinese herbs for H1N1
influenza. Almost all the trials claimed positive effect of Chinese
herbs though some of them turned out to be negative when
analyzed by standard statistical techniques using risk ratios or
mean differences. We undertook extensive searches for unpub-
lished material, but found no unpublished ‘negative’ studies as in
previous study [61]. We thought this might be attributed to the
lack of awareness to register clinical trials in China, the rejection of
journal editors to negative trials, and the inaccessibility to
unpublished data. We hope that with increasing awareness of
prospective registration of clinical trials, publication of clinical trial
protocol and reporting of negative clinical trials, the picture may
change in the future.
The mechanism of Chinese herbs in the treatment of influenza
is complex. In traditional Chinese medicine (TCM), H1N1
influenza belongs to the scope of ‘cold’. In TCM, cold is
differentiated into two types: Wind-cold Syndrome and Wind-
heat Syndrome. The principles behind treating these two types
were different. Generally speaking, the principles behind treating
wind-cold syndrome are to: relieve external symptoms with drugs
which are pungent in flavour and warm in property; ventilate the
lungs and expel the pathogenic cold. The principles behind
treating wind-heat syndrome are to: relieve external symptoms
with drugs which are pungent in flavour and cool in property and
promote the dispersing function of the lungs and clear up
pathogenic wind heat [62,63]. In addition, previous studies
showed that administration of some Chinese herbs may have
beneficial immunomodulatory effects for rapid recovery of viral
infections [64,65]. However, in this review, it seems that compared
with oseltamivir, Chinese herbs might have better potential effects
on fever solution than viral shedding, which suggested that most of
Chinese herbs might not act as an antiviral.
Last but not least, there is a lack of information about quality
control for the development of the herbal preparations or for the
manufacture of the herbal products, which is a quite common
problem in Chinese clinical trials. Future trials should provide
information about standardization including compositions, quality
control, detailed regimen, and duration of treatment.
In summary, the reported beneficial effect from Chinese herbs
for H1N1 influenza can not be taken as confirmative conclusion.
To ensure evidence-based clinical practice, further rigorous
placebo-controlled, randomized trials are warranted. The follow-
ing methodological issues should be addressed: (i) methods used to
generate allocation sequence and allocation concealment; (ii)
double blinding with the use of adequate placebo; (iii) clear
descriptions of withdrawal/dropout during the trial and use of
intention-to-treat analysis; and (iv) reporting trials according to the
Chinese Herbal Medicines for Type A H1N1 Influenza
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literature searching, we identified several registered trials of
Chinese herbs for H1N1 influenza. We hope with the publication
of these ongoing trials in the future, new high-qualified evidence
will arise to provide clinical evidence for the use of Chinese herbs
for the H1N1 influenza.
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